Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia

Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended for secondary prevention in peripheral artery disease, but their effectiveness in patients with critical limb ischemia (CLI) is uncertain. We reviewed 464 patients with CLI who underwent diagnost...

Full description

Saved in:

Bibliographic Details
Published in:	Vascular medicine (London, England) Vol. 20; no. 3; pp. 237 - 244
Main Authors:	Armstrong, Ehrin J, Chen, Debbie C, Singh, Gagan D, Amsterdam, Ezra A, Laird, John R
Format:	Journal Article
Language:	English
Published:	London, England SAGE Publications 01.06.2015 Sage Publications Ltd
Subjects:	Aged Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Critical Illness Female Follow-Up Studies Humans Ischemia - complications Leg - blood supply Male Proto-Oncogene Proteins Receptors, G-Protein-Coupled Retrospective Studies Time Factors peripheral artery disease critical limb ischemia guideline therapies adherence angiotensin converting enzyme inhibitor angiotensin receptor blocker prevention
ISSN:	1358-863X, 1477-0377
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended for secondary prevention in peripheral artery disease, but their effectiveness in patients with critical limb ischemia (CLI) is uncertain. We reviewed 464 patients with CLI who underwent diagnostic angiography or endovascular intervention from 2006–2013 at a multidisciplinary vascular center. ACEI or ARB use was assessed at the time of angiography. Major adverse cardiovascular events (MACE), mortality, and major adverse limb events (MALE) were assessed during three-year follow-up. Propensity weighting was used to adjust for baseline differences between patients taking and not taking ACEIs or ARBs. ACEIs or ARBs were prescribed to 269 (58%) patients. Patients prescribed ACEIs or ARBs had more baseline comorbidities including diabetes and hypertension (p<0.05). Patients prescribed ACEIs or ARBs had lower three-year unadjusted rates of MACE (40% versus 47%) and mortality (33% versus 43%). After propensity weighting, ACEI or ARB use was associated with significantly lower rates of MACE (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.58–0.99, p=0.04) and overall mortality (HR 0.71, 95% CI 0.53–0.95, p=0.02). There was no significant association between ACEI or ARB use and MALE (HR 0.97, 95% CI 0.69–1.35, p=0.2) or major amputation (HR 0.74, 95% CI 0.47–1.18, p=0.1). ACEI/ARB use is associated with lower MACE and mortality in patients with CLI, but there was no effect on limb-related outcomes.
AbstractList	Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended for secondary prevention in peripheral artery disease, but their effectiveness in patients with critical limb ischemia (CLI) is uncertain. We reviewed 464 patients with CLI who underwent diagnostic angiography or endovascular intervention from 2006–2013 at a multidisciplinary vascular center. ACEI or ARB use was assessed at the time of angiography. Major adverse cardiovascular events (MACE), mortality, and major adverse limb events (MALE) were assessed during three-year follow-up. Propensity weighting was used to adjust for baseline differences between patients taking and not taking ACEIs or ARBs. ACEIs or ARBs were prescribed to 269 (58%) patients. Patients prescribed ACEIs or ARBs had more baseline comorbidities including diabetes and hypertension ( p<0.05). Patients prescribed ACEIs or ARBs had lower three-year unadjusted rates of MACE (40% versus 47%) and mortality (33% versus 43%). After propensity weighting, ACEI or ARB use was associated with significantly lower rates of MACE (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.58–0.99, p=0.04) and overall mortality (HR 0.71, 95% CI 0.53–0.95, p=0.02). There was no significant association between ACEI or ARB use and MALE (HR 0.97, 95% CI 0.69–1.35, p=0.2) or major amputation (HR 0.74, 95% CI 0.47–1.18, p=0.1). ACEI/ARB use is associated with lower MACE and mortality in patients with CLI, but there was no effect on limb-related outcomes.
Author	Amsterdam, Ezra A Armstrong, Ehrin J Singh, Gagan D Laird, John R Chen, Debbie C
Author_xml	– sequence: 1 givenname: Ehrin J surname: Armstrong fullname: Armstrong, Ehrin J – sequence: 2 givenname: Debbie C surname: Chen fullname: Chen, Debbie C – sequence: 3 givenname: Gagan D surname: Singh fullname: Singh, Gagan D – sequence: 4 givenname: Ezra A surname: Amsterdam fullname: Amsterdam, Ezra A – sequence: 5 givenname: John R surname: Laird fullname: Laird, John R email: john.laird@ucdmc.ucdavis.edu
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25835349$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU1r3DAQhkVJaD7ae0_F0EsvbkaWZNnHENq0EOilgdyMJI93tbWlrSRvSf9X_1_kbELLQgsCaWae951Bc0aOnHdIyBsKHyiV8oIy0TQ1u6NCSM4q-oKcUi5lCUzKo_zO5XKpn5CzGDcAIOuWviQnlWiYYLw9Jb8v3cr6hC5aVxrvdhiSdasC3a_7CQvr1lbb5EORj_qDFgENbpe8Hr35jqGYY6ZjoWL0xqqEffHTpnXm-tnkYFKbxaHP_hk0KvTW71Q086hCgTt0KWsnnztvVbKP4aPeBJusUWMx2knnBmaNk1WvyPGgxoivn-5zcvvp47erz-XN1-svV5c3peEgU8kkNwO2BhVw7PvKmBqEglaLqtUgBlYPrG9BY20kQK2FRioH3UPVyqFimp2T93vfbfA_Zoypm_IIOI7KoZ9jR-uGc8YbDhl9d4Bu_Bxcnm6hBFCoJc3U2ydq1hP23TbYSYX77nkhGaj3gAk-xoBDZ2zKP-JdCsqOHYVu2Xx3uPkshAPhs_d_JOVeEtUK_xr3X_wDyYTBkA
CitedBy_id	crossref_primary_10_1016_j_amjmed_2018_07_006 crossref_primary_10_1371_journal_pone_0330522 crossref_primary_10_1016_j_jvs_2020_02_041 crossref_primary_10_1016_j_coph_2018_01_009 crossref_primary_10_1016_j_amjcard_2016_12_023 crossref_primary_10_1007_s11886_019_1227_4 crossref_primary_10_1177_1358863X20987612 crossref_primary_10_1007_s11936_024_01070_2 crossref_primary_10_1038_s41569_018_0005_0 crossref_primary_10_3390_jcm12113652 crossref_primary_10_1007_s11936_016_0464_8 crossref_primary_10_1016_j_jvs_2023_08_103 crossref_primary_10_1177_1358863X16636955 crossref_primary_10_23736_S0021_9509_19_11108_1 crossref_primary_10_1177_2047487319880044 crossref_primary_10_1002_ccd_26512 crossref_primary_10_1161_JAHA_121_024279 crossref_primary_10_1016_j_jacr_2016_03_008 crossref_primary_10_1016_j_amjmed_2019_04_043 crossref_primary_10_17116_kardio20241701182 crossref_primary_10_3389_fphar_2024_1464689 crossref_primary_10_1111_xen_12693 crossref_primary_10_1016_j_eclinm_2025_103391 crossref_primary_10_1097_HCO_0000000000000983 crossref_primary_10_1177_1358863X17714153 crossref_primary_10_1016_j_jvs_2017_07_130 crossref_primary_10_1080_14779072_2020_1736562 crossref_primary_10_1161_CIR_0000000000001251 crossref_primary_10_2147_VHRM_S246528 crossref_primary_10_1177_08971900241250084 crossref_primary_10_4239_wjd_v13_i12_1014 crossref_primary_10_1097_TP_0000000000003518 crossref_primary_10_1016_j_jvs_2024_09_008 crossref_primary_10_1177_1526602819826593 crossref_primary_10_1016_j_jjcc_2019_12_011 crossref_primary_10_1136_heartjnl_2015_309076 crossref_primary_10_1016_j_cjca_2022_02_029 crossref_primary_10_1080_14779072_2021_1914590 crossref_primary_10_1016_j_tvir_2024_100953 crossref_primary_10_1097_HCO_0000000000001226 crossref_primary_10_1080_14656566_2020_1774556 crossref_primary_10_1111_ans_18580 crossref_primary_10_1093_eurheartj_suaa079 crossref_primary_10_1016_j_jacc_2015_12_049 crossref_primary_10_1093_eurheartj_ehx095 crossref_primary_10_1016_j_ejvs_2017_07_018 crossref_primary_10_1161_JAHA_119_015451 crossref_primary_10_1016_j_avsg_2019_08_093 crossref_primary_10_1016_j_jacc_2024_02_013 crossref_primary_10_1016_j_lpm_2023_104164 crossref_primary_10_1016_j_jdmv_2019_06_004 crossref_primary_10_1016_j_vph_2020_106764 crossref_primary_10_1097_FJC_0000000000001556 crossref_primary_10_3390_ijms22042002 crossref_primary_10_1161_ATVBAHA_119_312142 crossref_primary_10_1016_j_iccl_2024_11_002 crossref_primary_10_1253_circj_CJ_25_0086 crossref_primary_10_3390_jcm14155309
Cites_doi	10.1186/1471-2261-5-14 10.1161/01.CIR.93.6.1073 10.1161/01.CIR.90.4.2056 10.1001/jama.2012.216237 10.1191/1358863x03vm502oa 10.1161/CIRCOUTCOMES.109.930735 10.1177/1358863X14550543 10.1177/000331978503600505 10.1161/01.CIR.99.23.3043 10.1016/j.atherosclerosis.2008.10.023 10.1097/MLR.0b013e31806518ac 10.1056/NEJM199209033271001 10.1016/j.jacc.2013.09.073 10.1161/CIRCULATIONAHA.105.548461 10.1161/01.CIR.103.7.919 10.1161/JAHA.113.000697 10.1016/S0140-6736(96)09457-3 10.1016/S0140-6736(02)09327-3 10.1097/00004872-199715070-00012 10.1016/j.jvs.2009.08.073 10.1161/HYPERTENSIONAHA.107.097394 10.2147/vhrm.2007.3.2.229 10.1016/j.ehj.2003.10.033 10.1161/01.HYP.15.3.327 10.1177/000331978803901103 10.1093/biomet/70.1.41 10.1016/S0008-6363(01)00372-8 10.1056/NEJM199202063260605 10.1007/s11606-006-5042-4 10.1161/CIRCRESAHA.114.302420 10.1016/j.jvs.2013.03.050 10.1056/NEJMoa0801317 10.1097/HJH.0b013e328306ebe2 10.1016/j.jacc.2005.10.009 10.1016/j.jacc.2007.11.077 10.1016/S0140-6736(87)92441-X 10.1161/01.CIR.95.6.1532 10.1016/j.cmpb.2003.10.004 10.1016/S0140-6736(13)61249-0 10.1161/CIRCULATIONAHA.110.003954 10.1056/NEJM200001203420301 10.1253/circj.67.535 10.1161/CIRCULATIONAHA.106.174526 10.1016/j.jacc.2005.09.074 10.1161/CIR.0b013e3182031a3c 10.1001/jama.286.11.1317 10.1253/circj.CJ-08-1169 10.1016/j.jvs.2006.12.037 10.1016/S0140-6736(13)61576-7 10.1177/1358863X13475836
ContentType	Journal Article
Copyright	The Author(s) 2015 The Author(s) 2015. SAGE Publications © Jun 2015
Copyright_xml	– notice: The Author(s) 2015 – notice: The Author(s) 2015. – notice: SAGE Publications © Jun 2015
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1177/1358863X15574321
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE Technology Research Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1477-0377
EndPage	244
ExternalDocumentID	3702048031 25835349 10_1177_1358863X15574321 10.1177_1358863X15574321
Genre	Clinical Study Journal Article Feature
GroupedDBID	--- -TM .2E .2J .2N 01A 0R~ 123 1~K 29Q 31R 31U 31X 31Z 36B 4.4 53G 54M 5RE 5VS 7X7 88E 8FI 8FJ 8R4 8R5 AABMB AACKU AACMV AACTG AADUE AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAKDD AAKGS AANSI AAPEO AAQGT AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABHQH ABIDT ABJNI ABJZC ABKRH ABLUO ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABXGC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFS ACGZU ACIWK ACJER ACJTF ACLFY ACLHI ACLZU ACOFE ACOXC ACPRK ACROE ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADMPF ADNBR ADNON ADRRZ ADSTG ADTBJ ADUKL ADVBO ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFRAH AFUIA AGHKR AGKLV AGNHF AGPXR AGWFA AGWNL AHDMH AHJOV AHMBA AIGRN AIIQI AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV AUTPY AUVAJ AYAKG B3H B8M B8R B8Z B94 BAWUL BBRGL BDDNI BENPR BKIIM BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD C45 CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK DB0 DC- DC. DC0 DD- DD0 DE- DE. DF0 DIK DN0 DO- DOPDO DV7 DV9 EBS EJD EMOBN F5P FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HZ~ J8X K.F M1P N9A O9- OK1 OVD P.9 P.B PHGZM PHGZT PQQKQ PROAC PSQYO Q1R Q2X Q7L Q7U Q83 ROL S01 SASJQ SAUOL SCNPE SDB SFC SFK SFT SGO SGR SGV SGZ SHG SNB SPJ SPQ SPV STM TEORI UKHRP W8F ZONMY ZPPRI ZRKOI ZSSAH AAEJI AAPII AAYXX ABUAX AFFHD AJGYC AJHME AJVBE CITATION PJZUB PPXIY 3V. AADTT AAMGE ACSBE ACTQU AEUIJ AIOMO ALTZF CGR CUY CVF EAD EAP ECM EIF EMB EMK ESX M4V NPM SV3 7XB 8FD 8FK FR3 K9. M7Z P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c407t-374cfe9cea04edd2cc605a09b529b05f36f3d90be6c7006b5be17fbd0297f23b3
IEDL.DBID	7X7
ISICitedReferencesCount	64
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000355334000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1358-863X
IngestDate	Mon Sep 29 05:41:04 EDT 2025 Mon Oct 06 17:39:10 EDT 2025 Wed Feb 19 02:08:37 EST 2025 Sat Nov 29 08:14:19 EST 2025 Tue Nov 18 20:47:43 EST 2025 Tue Jun 17 22:31:29 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	peripheral artery disease critical limb ischemia guideline therapies adherence angiotensin converting enzyme inhibitor angiotensin receptor blocker prevention
Language	English
License	The Author(s) 2015.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c407t-374cfe9cea04edd2cc605a09b529b05f36f3d90be6c7006b5be17fbd0297f23b3
Notes	SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://journals.sagepub.com/doi/pdf/10.1177/1358863X15574321
PMID	25835349
PQID	1685010671
PQPubID	38690
PageCount	8
ParticipantIDs	proquest_miscellaneous_1684434840 proquest_journals_1685010671 pubmed_primary_25835349 crossref_citationtrail_10_1177_1358863X15574321 crossref_primary_10_1177_1358863X15574321 sage_journals_10_1177_1358863X15574321
PublicationCentury	2000
PublicationDate	2015-06-01
PublicationDateYYYYMMDD	2015-06-01
PublicationDate_xml	– month: 06 year: 2015 text: 2015-06-01 day: 01
PublicationDecade	2010
PublicationPlace	London, England
PublicationPlace_xml	– name: London, England – name: England – name: London
PublicationTitle	Vascular medicine (London, England)
PublicationTitleAlternate	Vasc Med
PublicationYear	2015
Publisher	SAGE Publications Sage Publications Ltd
Publisher_xml	– name: SAGE Publications – name: Sage Publications Ltd
References	Armstrong, Chen, Westin 2014; 3 Bernardi, Bartoli, Ferreri 1988; 39 Caro, Migliaccio-Walle, Ishak 2005; 5 Hirsch, Duval 2013; 382 Ahimastos, Walker, Askew 2013; 309 Varu, Hogg, Kibbe 2010; 51 Criqui, Langer, Fronek 1992; 326 Gustafsson, Torp-Pedersen, Køber 1997; 15 1996; 348 Pande, Perlstein, Beckman 2011; 124 Welten, Schouten, Hoeks 2008; 51 Hernández-Presa, Bustos, Ortego 1997; 95 Fabre, Rivard, Magner 1999; 99 Ahimastos, Latouche, Natoli 2014; 114 Roberts, Tsao, McLoughlin 1987; 2 Westin, Armstrong, Bang 2014; 63 Hirsch, Haskal, Hertzer 2006; 47 Chobanian, Haudenschild, Nickerson 1990; 15 2008; 358 Fowkes, Rudan, Rudan 2013; 382 Lonn, Yusuf, Jha 1994; 90 Lonn, Yusuf, Dzavik 2001; 103 Feringa, van Waning, Bax 2006; 47 Cole, Hernán 2004; 75 McDermott, Mehta 1997; 12 Hamdan, Quist, Gagne 1996; 93 Catalano, Libretti 1985; 36 Mahoney, Wang, Keo 2010; 3 Li, Kondo, Numaguchi 2008; 51 Takeshita, Tomiyama, Yokoyama 2001; 52 Norgren, Hiatt, Dormandy 2007; 45 Shammas 2007; 3 Rosenbaum, Rubin 1983; 70 Vanhoutte 2009; 73 2006; 113 Pfeffer, Braunwald, Moyé 1992; 327 Bosch, Lonn, Pogue 2005; 112 Hirsch, Duprez 2003; 8 McCoach, Armstrong, Singh 2013; 18 Olin, Allie, Belkin 2010; 122 2002; 360 Östergren 2004; 25 Cacoub, Abola, Baumgartner 2009; 204 Curtis, Hammill, Eisenstein 2007; 45 Novo, Abrignani, Pavone 1996; 15 Miura, Nishikawa, Zhang 2003; 67 Chung, Timaran, Modrall 2013; 58 Yusuf, Sleight, Pogue 2000; 342 Van de Ven, Van Leeuwen, Smit 1994; 23 Slovut, Kargoli, Fletcher 2014; 19 Reboldi, Angeli, Cavallini 2008; 26 Hirsch, Criqui, Treat-Jacobson 2001; 286 bibr16-1358863X15574321 bibr3-1358863X15574321 bibr24-1358863X15574321 bibr25-1358863X15574321 Novo S (bibr41-1358863X15574321) 1996; 15 bibr17-1358863X15574321 bibr32-1358863X15574321 bibr26-1358863X15574321 bibr23-1358863X15574321 bibr40-1358863X15574321 bibr4-1358863X15574321 bibr18-1358863X15574321 bibr31-1358863X15574321 bibr22-1358863X15574321 bibr35-1358863X15574321 bibr5-1358863X15574321 bibr49-1358863X15574321 bibr51-1358863X15574321 bibr43-1358863X15574321 bibr36-1358863X15574321 bibr30-1358863X15574321 bibr28-1358863X15574321 bibr15-1358863X15574321 Van de Ven L (bibr39-1358863X15574321) 1994; 23 bibr2-1358863X15574321 bibr7-1358863X15574321 bibr12-1358863X15574321 bibr20-1358863X15574321 bibr33-1358863X15574321 bibr46-1358863X15574321 bibr11-1358863X15574321 bibr29-1358863X15574321 bibr38-1358863X15574321 bibr8-1358863X15574321 bibr45-1358863X15574321 bibr47-1358863X15574321 bibr9-1358863X15574321 bibr10-1358863X15574321 bibr44-1358863X15574321 bibr48-1358863X15574321 bibr14-1358863X15574321 bibr52-1358863X15574321 bibr27-1358863X15574321 bibr13-1358863X15574321 bibr1-1358863X15574321 bibr19-1358863X15574321 bibr34-1358863X15574321 bibr21-1358863X15574321 bibr42-1358863X15574321 bibr6-1358863X15574321 bibr37-1358863X15574321 bibr50-1358863X15574321
References_xml	– volume: 47 start-page: 1182 year: 2006 end-page: 1187 article-title: Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease publication-title: J Am Coll Cardiol – volume: 3 start-page: 642 year: 2010 end-page: 651 article-title: Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States publication-title: Circ Cardiovasc Qual Outcomes – volume: 95 start-page: 1532 year: 1997 end-page: 1541 article-title: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis publication-title: Circulation – volume: 75 start-page: 45 year: 2004 end-page: 49 article-title: Adjusted survival curves with inverse probability weights publication-title: Comput Methods Programs Biomed – volume: 26 start-page: 1282 year: 2008 end-page: 1289 article-title: Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis publication-title: J Hypertens – volume: 327 start-page: 669 year: 1992 end-page: 677 article-title: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators publication-title: N Engl J Med – volume: 5 start-page: 14 year: 2005 article-title: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database publication-title: BMC Cardiovasc Disord – volume: 58 start-page: 972 year: 2013 end-page: 980 article-title: Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia publication-title: J Vasc Surg – volume: 90 start-page: 2056 year: 1994 end-page: 2069 article-title: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection publication-title: Circulation – volume: 382 start-page: 1312 year: 2013 end-page: 1314 article-title: The global pandemic of peripheral artery disease publication-title: The Lancet – volume: 51 start-page: 252 year: 2008 end-page: 258 article-title: Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis publication-title: Hypertension – volume: 112 start-page: 1339 year: 2005 end-page: 1346 article-title: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension publication-title: Circulation – volume: 2 start-page: 650 year: 1987 end-page: 653 article-title: Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication publication-title: Lancet – volume: 358 start-page: 1547 year: 2008 end-page: 1559 article-title: Telmisartan, ramipril, or both in patients at high risk for vascular events publication-title: N Engl J Med – volume: 18 start-page: 19 year: 2013 end-page: 26 article-title: Gender-related variation in the clinical presentation and outcomes of critical limb ischemia publication-title: Vasc Med – volume: 51 start-page: 230 year: 2010 end-page: 241 article-title: Critical limb ischemia publication-title: J Vasc Surg – volume: 204 start-page: e86 year: 2009 end-page: e92 article-title: Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry publication-title: Atherosclerosis – volume: 93 start-page: 1073 year: 1996 end-page: 1078 article-title: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta publication-title: Circulation – volume: 3 start-page: 229 year: 2007 end-page: 234 article-title: Epidemiology, classification, and modifiable risk factors of peripheral arterial disease publication-title: Vasc Health Risk Manag – volume: 23 start-page: 357 year: 1994 end-page: 362 article-title: The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication: a comparative cross-over trial publication-title: VASA – volume: 19 start-page: 368 year: 2014 end-page: 375 article-title: Quality of care among patients undergoing lower extremity revascularization publication-title: Vasc Med – volume: 382 start-page: 1329 year: 2013 end-page: 1340 article-title: Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis publication-title: The Lancet – volume: 326 start-page: 381 year: 1992 end-page: 386 article-title: Mortality over a period of 10 years in patients with peripheral arterial disease publication-title: N Engl J Med – volume: 309 start-page: 453 year: 2013 end-page: 460 article-title: Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial publication-title: J Am Med Assoc – volume: 8 start-page: 273 year: 2003 end-page: 278 article-title: The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease publication-title: Vasc Med – volume: 124 start-page: 17 year: 2011 end-page: 23 article-title: Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004 publication-title: Circulation – volume: 103 start-page: 919 year: 2001 end-page: 925 article-title: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) publication-title: Circulation – volume: 47 start-page: 1239 year: 2006 end-page: 1312 article-title: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation publication-title: J Am Coll Cardiol – volume: 67 start-page: 535 year: 2003 end-page: 538 article-title: Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease publication-title: Circ J – volume: 63 start-page: 682 year: 2014 end-page: 690 article-title: Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia publication-title: J Am Coll Cardiol – volume: 15 start-page: 793 year: 1997 end-page: 798 article-title: Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event publication-title: J Hypertens – volume: 45 start-page: S5 year: 2007 end-page: S67 article-title: Inter-society consensus for the management of peripheral arterial disease (TASC II) publication-title: J Vasc Surg – volume: 99 start-page: 3043 year: 1999 end-page: 3049 article-title: Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo publication-title: Circulation – volume: 52 start-page: 314 year: 2001 end-page: 320 article-title: Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats publication-title: Cardiovasc Res – volume: 73 start-page: 595 year: 2009 end-page: 601 article-title: Endothelial dysfunction: the first step toward coronary arteriosclerosis publication-title: Circ J – volume: 15 start-page: 327 year: 1990 end-page: 331 article-title: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit publication-title: Hypertension – volume: 360 start-page: 7 issue: 9326 year: 2002 end-page: 22 article-title: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial publication-title: Lancet – volume: 113 start-page: e463 year: 2006 end-page: e465 publication-title: Circulation – volume: 51 start-page: 1588 year: 2008 end-page: 1596 article-title: Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease publication-title: J Am Coll Cardiol – volume: 36 start-page: 293 year: 1985 end-page: 296 article-title: Captopril for the treatment of patients with hypertension and peripheral vascular disease publication-title: Angiology – volume: 3 start-page: e000697 year: 2014 article-title: Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease publication-title: J Am Heart Assoc – volume: 348 start-page: 1329 issue: 9038 year: 1996 end-page: 1339 article-title: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) publication-title: Lancet – volume: 45 start-page: S103 year: 2007 end-page: S107 article-title: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases publication-title: Med Care – volume: 15 start-page: 169 year: 1996 end-page: 174 article-title: Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication publication-title: Int Angiol J Int Union Angiol – volume: 122 start-page: 2583 year: 2010 end-page: 2618 article-title: ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (writing committee to develop clinical performance measures for peripheral artery disease) publication-title: Circulation – volume: 114 start-page: 1144 year: 2014 end-page: 1155 article-title: Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication publication-title: Circ Res – volume: 25 start-page: 17 year: 2004 end-page: 24 article-title: Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease publication-title: Eur Heart J – volume: 342 start-page: 145 year: 2000 end-page: 153 article-title: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators publication-title: N Engl J Med – volume: 70 start-page: 41 year: 1983 end-page: 55 article-title: The central role of the propensity score in observational studies for causal effects publication-title: Biometrika – volume: 12 start-page: 209 year: 1997 end-page: 215 article-title: Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease publication-title: J Gen Intern Med – volume: 39 start-page: 942 year: 1988 end-page: 952 article-title: Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound publication-title: Angiology – volume: 286 start-page: 1317 year: 2001 end-page: 1324 article-title: Peripheral arterial disease detection, awareness, and treatment in primary care publication-title: J Am Med Assoc – ident: bibr24-1358863X15574321 doi: 10.1186/1471-2261-5-14 – ident: bibr14-1358863X15574321 doi: 10.1161/01.CIR.93.6.1073 – ident: bibr32-1358863X15574321 doi: 10.1161/01.CIR.90.4.2056 – ident: bibr12-1358863X15574321 doi: 10.1001/jama.2012.216237 – ident: bibr9-1358863X15574321 doi: 10.1191/1358863x03vm502oa – ident: bibr23-1358863X15574321 doi: 10.1161/CIRCOUTCOMES.109.930735 – ident: bibr43-1358863X15574321 doi: 10.1177/1358863X14550543 – ident: bibr40-1358863X15574321 doi: 10.1177/000331978503600505 – ident: bibr30-1358863X15574321 doi: 10.1161/01.CIR.99.23.3043 – ident: bibr52-1358863X15574321 doi: 10.1016/j.atherosclerosis.2008.10.023 – ident: bibr19-1358863X15574321 doi: 10.1097/MLR.0b013e31806518ac – ident: bibr10-1358863X15574321 doi: 10.1056/NEJM199209033271001 – ident: bibr50-1358863X15574321 doi: 10.1016/j.jacc.2013.09.073 – ident: bibr7-1358863X15574321 doi: 10.1161/CIRCULATIONAHA.105.548461 – ident: bibr13-1358863X15574321 doi: 10.1161/01.CIR.103.7.919 – ident: bibr51-1358863X15574321 doi: 10.1161/JAHA.113.000697 – ident: bibr48-1358863X15574321 doi: 10.1016/S0140-6736(96)09457-3 – ident: bibr49-1358863X15574321 doi: 10.1016/S0140-6736(02)09327-3 – ident: bibr11-1358863X15574321 doi: 10.1097/00004872-199715070-00012 – ident: bibr3-1358863X15574321 doi: 10.1016/j.jvs.2009.08.073 – ident: bibr29-1358863X15574321 doi: 10.1161/HYPERTENSIONAHA.107.097394 – ident: bibr25-1358863X15574321 doi: 10.2147/vhrm.2007.3.2.229 – ident: bibr27-1358863X15574321 doi: 10.1016/j.ehj.2003.10.033 – ident: bibr34-1358863X15574321 doi: 10.1161/01.HYP.15.3.327 – ident: bibr37-1358863X15574321 doi: 10.1177/000331978803901103 – ident: bibr18-1358863X15574321 doi: 10.1093/biomet/70.1.41 – ident: bibr31-1358863X15574321 doi: 10.1016/S0008-6363(01)00372-8 – ident: bibr21-1358863X15574321 doi: 10.1056/NEJM199202063260605 – ident: bibr47-1358863X15574321 doi: 10.1007/s11606-006-5042-4 – ident: bibr36-1358863X15574321 doi: 10.1161/CIRCRESAHA.114.302420 – ident: bibr42-1358863X15574321 doi: 10.1016/j.jvs.2013.03.050 – ident: bibr28-1358863X15574321 doi: 10.1056/NEJMoa0801317 – ident: bibr45-1358863X15574321 doi: 10.1097/HJH.0b013e328306ebe2 – ident: bibr26-1358863X15574321 doi: 10.1016/j.jacc.2005.10.009 – ident: bibr22-1358863X15574321 doi: 10.1016/j.jacc.2007.11.077 – ident: bibr38-1358863X15574321 doi: 10.1016/S0140-6736(87)92441-X – ident: bibr15-1358863X15574321 doi: 10.1161/01.CIR.95.6.1532 – volume: 23 start-page: 357 year: 1994 ident: bibr39-1358863X15574321 publication-title: VASA – ident: bibr20-1358863X15574321 doi: 10.1016/j.cmpb.2003.10.004 – ident: bibr1-1358863X15574321 doi: 10.1016/S0140-6736(13)61249-0 – ident: bibr44-1358863X15574321 doi: 10.1161/CIRCULATIONAHA.110.003954 – ident: bibr6-1358863X15574321 doi: 10.1056/NEJM200001203420301 – ident: bibr35-1358863X15574321 doi: 10.1253/circj.67.535 – volume: 15 start-page: 169 year: 1996 ident: bibr41-1358863X15574321 publication-title: Int Angiol J Int Union Angiol – ident: bibr5-1358863X15574321 doi: 10.1161/CIRCULATIONAHA.106.174526 – ident: bibr8-1358863X15574321 doi: 10.1016/j.jacc.2005.09.074 – ident: bibr16-1358863X15574321 doi: 10.1161/CIR.0b013e3182031a3c – ident: bibr46-1358863X15574321 doi: 10.1001/jama.286.11.1317 – ident: bibr33-1358863X15574321 doi: 10.1253/circj.CJ-08-1169 – ident: bibr4-1358863X15574321 doi: 10.1016/j.jvs.2006.12.037 – ident: bibr2-1358863X15574321 doi: 10.1016/S0140-6736(13)61576-7 – ident: bibr17-1358863X15574321 doi: 10.1177/1358863X13475836
SSID	ssj0007691
Score	2.3413363
Snippet	Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended for secondary prevention in peripheral artery disease,...
SourceID	proquest pubmed crossref sage
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	237
SubjectTerms	Aged Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Critical Illness Female Follow-Up Studies Humans Ischemia - complications Leg - blood supply Male Proto-Oncogene Proteins Receptors, G-Protein-Coupled Retrospective Studies Time Factors
Title	Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia
URI	https://journals.sagepub.com/doi/full/10.1177/1358863X15574321 https://www.ncbi.nlm.nih.gov/pubmed/25835349 https://www.proquest.com/docview/1685010671 https://www.proquest.com/docview/1684434840
Volume	20
WOSCitedRecordID	wos000355334000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1477-0377 dateEnd: 20151231 omitProxy: false ssIdentifier: ssj0007691 issn: 1358-863X databaseCode: 7X7 dateStart: 19980201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1477-0377 dateEnd: 20151231 omitProxy: false ssIdentifier: ssj0007691 issn: 1358-863X databaseCode: BENPR dateStart: 19980201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD6CDSFeuF8CYzISQuIhahzbSfw0DbSJB6gmBKhvVXwb2da0NC0S_C_-344dt6Ug9oIU5cE5ji35-Fzso-8DeFloJV1VFamjeZlySmUqK8dTTbXIDDOlCCX_X96Xw2E1GsmTeODWxbLKlU0MhtpMtT8jH9CiEgHvjB7MvqWeNcrfrkYKjeuw62mzPXZ-OVonXJiiyz7hElVaFWy0uaYc-DbfhO4UfWhOt93SX7HmVp1XcD3Hd_530nfhdgw6yWGvJffgmm3vw80P8Vr9Afw6bE-baahlb9NQh-6xBU6JbX_-mFjStF8bhTt_TvCpN6IEraWd-XaFLvHczsmyQ-mO1HHNrSH-nBflDGqQIZP6zP_Bc0CjoN4qhSUBSgr7evYjEuFeu76_jnwM5KKZKBxAe5SD-iF8Pj769PZdGvkcUo1p4wJtGdfOSm3rjFtjcq0xl6ozqUQuVSYcKxwzMlO20CUaAyWUpaVTxvNruZwp9gh22mlrnwBxSmQY2RUsd5wzY2uqZGYxd9QYnnGZJTBYLedYR7Bzz7lxMaYR3_xPBUjg9brHrAf6uEJ2b7Xc47jlu_FmrRN4sf6Mm9XfwNStnS6DDE6XY1KdwONes9aD5QKDYcZlAq-8qv3243_M4unVs3gGtzC4E31Z2x7sLOZL-xxu6O-Lppvvh40S3tU-7L45Gp58vARNUxzT
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAL78dCASMBEodo7cRO4gNCFVC16nbFoaC9hfhVAt3sstkFlR_Fjf_HOI9dFkRvPSDl5IwdK_k8D_vLDMCTWCvp0jQOHAuTgDMmA5k6HmimBTWRSURN-X8_SIbDdDSSbzfgR_cvjKdVdjqxVtRmov0eeZ_FqajznbGX0y-BrxrlT1e7EhoNLPbtyTcM2aoXe6_x-z4Nw503h692g7aqQKAxeJnjiuLaWaltTrk1JtQaPfqcSiVCqahwUewiI6mysU4QkkooyxKnjK_y5MJIRTjuOTiPejzxFLJktAzwaBLLJsATaZDG0Wh1LNr3bb4JzTfa7JCtm8G_fNs1Xllt6nau_m8v6RpcaZ1qst2sguuwYcsbcPGgpQ3chJ_b5VExqbn6ZVDz7H3uhCNiy-8nY0uK8mOhULPNCF75SpSgNbBT367Q5H-2M7KoULoieYtpa4jfx0Y5gyvEkHH-yY_ga1yjoF6j-pI6VRb29dWdSJvOtmr667beBDkuxgofoH0Wh_wWvDuTl3YbNstJae8CcUpQ9FzjKHScR8bmTElqMTbW6H5ySXvQ7-CT6TaZu68pcpyxNn_7n4DrwfNlj2mTyOQU2a0OXlmr0qpsha0ePF7eRmXkT5jy0k4WtQxOl6ccJ3inQfLyYaFAZz_isgfPPLR_G_gfs7h3-iwewaXdw4NBNtgb7t-Hy-jIiobCtwWb89nCPoAL-uu8qGYP60VK4MNZA_4X_Zl5CQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Angiotensin-converting+enzyme+inhibitor+or+angiotensin+receptor+blocker+use+is+associated+with+reduced+major+adverse+cardiovascular+events+among+patients+with+critical+limb+ischemia&rft.jtitle=Vascular+medicine+%28London%2C+England%29&rft.au=Armstrong%2C+Ehrin+J&rft.au=Chen%2C+Debbie+C&rft.au=Singh%2C+Gagan+D&rft.au=Amsterdam%2C+Ezra+A&rft.date=2015-06-01&rft.eissn=1477-0377&rft.volume=20&rft.issue=3&rft.spage=237&rft.epage=244&rft_id=info:doi/10.1177%2F1358863X15574321&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1358-863X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1358-863X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1358-863X&client=summon